Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ala-2-naphthylamide + H2O
Ala + 2-naphthylamine
-
-
-
-
?
Ala-4-nitroanilide + H2O
Ala + 4-nitroaniline
-
4.6% of the activity with Leu-4-nitroanilide
-
?
Ala-Ala 4-nitroanilide + H2O
Ala-Ala + 4-nitroaniline
alpha-Glu-4-nitroanilide + H2O
Glu + 4-nitroaniline
-
564% of the activity with Leu-4-nitroanilide
-
?
angiotensin III + H2O
angiotensin IV + ?
-
-
-
-
?
Arg 4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Arg-4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
?
Arg-4-nitroanilide + H2O
Arg + 4-nitroaniline
Arg-7-amido-4-methylcoumarin + H2O
Arg + 7-amino-4-methylcoumarin
Arg-Ala + H2O
Arg + Ala
-
82% of the activity with Arg-Arg
-
?
Arg-alpha-atrial natriuretic factor1-20 + H2O
Arg + alpha-atrial natriuretic factor1-20
-
-
-
-
?
Arg-Arg + H2O
Arg + Arg
-
-
-
?
Arg-Asp + H2O
Arg + Asp
-
25% of the activity with Arg-Arg
-
?
Arg-beta-atrial natriuretic factor1-20 + H2O
Arg + beta-atrial natriuretic factor1-20
-
-
-
-
?
Arg-beta-naphthylamide + H2O
L-arginine + 2-naphthylamine
-
substrate used in the activity assay
-
-
?
Arg-Gly + H2O
Arg + Gly
-
-
?
Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro + H2O
Arg + Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro
i.e. fibronectin-binding inhibitor
-
?
Arg-Gly-Glu-Ser + H2O
Arg + Gly-Glu-Ser
i.e. platelet aggregation inhibitor
-
?
Arg-Gly-Pro-Phe-Pro-Ile + H2O
Arg + Gly-Pro-Phe-Pro-Ile
i.e. sexual agglutination peptide
-
?
Arg-Gly-Tyr-Ala-Leu-Gly + H2O
Arg + Gly-Tyr-Ala-Leu-Gly
-
-
-
-
?
Arg-Ile + H2O
Arg + Ile
-
32% of the activity with Arg-Arg
-
?
Arg-Leu + H2O
Arg + Leu
-
25% of the activity with Arg-Arg
-
?
Arg-Leu-enkephalin + H2O
Arg + Leu-enkephalin
-
-
-
-
?
Arg-Lys + H2O
Arg + Lys
-
88% of the activity with Arg-Arg
-
?
Arg-Lys-Asp-Val-Tyr-OH + H2O
?
-
-
-
-
?
Arg-Lys-somatostatin-14 + 2 H2O
Arg + Lys + somatostatin-14
-
sequential removal of basic N-terminal residues
-
-
?
Arg-Lys-somatostatin-14 + H2O
Arg-Lys + somatostatin-14
-
-
-
-
?
Arg-Met-enkephalin + H2O
?
-
-
-
-
?
Arg-Met-enkephalin + H2O
Arg + Met-enkephalin
-
-
-
-
?
Arg-neurokinin A + H2O
Arg + neurokinin A
-
-
-
-
?
Arg-Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val + H2O
Arg + Phe-Ala-Arg-Lys-Gly-Ala-Leu-Arg-Gln-Lys-Asn-Val
i.e. protein kinase C substrate
-
?
Arg-Pro-Lys-Pro-Gln-Gly-Leu-Met + H2O
Arg + Pro-Lys-Pro-Gln-Gly-Leu-Met
i.e. substance P
-
?
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg + H2O
Arg + Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
Arg-Tyr-Leu-Pro-Thr + H2O
Arg + Tyr-Leu-Pro-Thr
-
proctolin
-
-
?
Arg-Val-Tyr-Ile-His-Pro-Ile + H2O
Arg + Val-Tyr-Ile-His-Pro-Ile
i.e. angiotensin III
-
?
Arg-Val-Tyr-Ile-His-Pro-Phe + H2O
Arg + Val-Tyr-Ile-His-Pro-Phe
-
angiotensin III
-
-
?
azocasein + H2O
?
-
-
-
-
?
azocasein + H2O
protein fragments of azocasein of MW 71 kDa, 83 kDa, and 22 kDa
-
-
-
-
?
benzoyl-Arg-p-nitroanilide + H2O
benzoyl-Arg + p-nitroaniline
-
-
-
-
?
Cys-Gly + H2O
Cys + Gly
-
4210% of the activity with Leu-4-nitroanilide
-
?
elastin Congo red + H2O
?
-
-
-
-
?
glucagon + H2O
miniglucagon + ?
-
-
-
-
?
Gly-2-naphthylamide + H2O
Gly + 2-naphthylamine
Gly-4-nitroanilide + H2O
Gly + 4-nitroaniline
-
1.3% of the activity with Leu-4-nitroanilide
-
?
Gly-L-Pro-2-naphthylamide + H2O
Gly-L-Pro + 2-naphthylamine
-
1% activity compared to L-Lys-2-naphthylamide
-
-
?
Gly-Phe 4-nitroanilide + H2O
Gly-Phe + 4-nitroaniline
kallidin + H2O
?
-
-
-
-
?
kallidin + H2O
bradykinin + ?
i.e. KRPPGFSPFR
-
-
?
kallidin-10 + H2O
Lys + bradykinin
-
-
-
-
?
L-Ala-2-naphthylamide + H2O
L-Ala + 2-naphthylamine
L-Ala-4-nitroanilide + H2O
L-Ala + 4-nitroaniline
L-Ala-7-amido-4-methylcoumarin + H2O
L-Ala + 7-amino-4-methylcoumarin
L-Ala-Ala-Pro-Leu-4-nitroanilide + H2O
L-Ala-Ala-Pro-Leu + 4-nitroaniline
-
-
-
-
?
L-Arg 7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
fluorogenic substrate, best substrate
-
-
?
L-Arg-(Met)enkephalin + H2O
L-Arg + (Met)enkephalin
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
L-Arg-4-nitroanilide + H2O
L-Arg + 4-nitroaniline
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
L-Arg-L-Tyr-Gly-Gly-L-Phe-L-Leu + H2O
L-Arg + L-Tyr-Gly-Gly-L-Phe-L-Leu
-
-
-
-
?
L-Arg-p-nitroanilide + H2O
L-Arg + p-nitroaniline
L-Arg-peptide + H2O
L-Arg + peptide
-
specific for N-terminal Arg or Lys residues, di-, tri-, and polypeptides
-
-
?
L-arginine-2-naphthylamide + H2O
2-naphthylamine + L-Arg
-
assay at 37°C
-
-
?
L-Asn-7-amido-4-methylcoumarin + H2O
L-Asn + 7-amino-4-methylcoumarin
53% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Asp-7-amido-4-methylcoumarin + H2O
L-Asp + 7-amino-4-methylcoumarin
15% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-beta-Asn-2-naphthylamide + H2O
L-beta-Asn + 2-naphthylamine
-
9% activity compared to L-Lys-2-naphthylamide
-
-
?
L-Cys-2-naphthylamide + H2O
L-Cys + 2-naphthylamine
-
1% activity compared to L-Lys-2-naphthylamide
-
-
?
L-Cys-7-amido-4-methylcoumarin + H2O
L-Cys + 7-amino-4-methylcoumarin
-
5% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Gln-7-amido-4-methylcoumarin + H2O
L-Gln + 7-amino-4-methylcoumarin
about 1% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Gly-L-Arg-2-naphthylamide + H2O
L-Gly-L-Arg + 2-naphthylamine
-
250% activity compared to L-Lys-2-naphthylamide
-
-
?
L-His-2-naphthylamide + H2O
L-His + 2-naphthylamine
-
15% activity compared to L-Lys-2-naphthylamide
-
-
?
L-Ile-7-amido-4-methylcoumarin + H2O
L-Ile + 7-amino-4-methylcoumarin
about 1% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Leu 7-amido-4-methylcoumarin + H2O
L-Leu + 7-amino-4-methylcoumarin
-
fluorogenic substrate
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
L-Leu-4-nitroanilide + H2O
L-Leu + 4-nitroaniline
L-Leu-7-amido-4-methylcoumarin + H2O
L-Leu + 7-amino-4-methylcoumarin
L-Lys-(Met)enkephalin + H2O
L-Lys + (Met)enkephalin
L-Lys-2-naphthylamide + H2O
L-Lys + 2-naphthylamine
L-Lys-4-nitroanilide + H2O
L-Lys + 4-nitroaniline
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
L-Lys-L-Ala-2-naphthylamide + H2O
L-Lys-L-Ala + 2-naphthylamine
-
7% activity compared to L-Lys-2-naphthylamide
-
-
?
L-Lys-p-nitroanilide + H2O
L-Lys + p-nitroaniline
-
-
-
-
?
L-Lys-peptide + H2O
L-Lys + peptide
-
specific for N-terminal Arg or Lys residues, di-, tri-, and polypeptide
-
-
?
L-lysine-2-naphthylamide + H2O
2-naphthylamine + L-Lys
-
assay at 37°C
-
-
?
L-Met-2-naphthylamide + H2O
L-Met + 2-naphthylamine
L-Met-7-amido-4-methylcoumarin + H2O
L-Met + 7-amino-4-methylcoumarin
L-Phe-2-naphthylamide + H2O
L-Phe + 2-naphthylamine
-
0.171% activity compared to L-Arg-2-naphthylamide
-
-
?
L-Phe-7-amido-4-methylcoumarin + H2O
L-Phe + 7-amino-4-methylcoumarin
L-Pro-7-amido-4-methylcoumarin + H2O
L-Pro + 7-amino-4-methylcoumarin
-
7% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Ser-7-amido-4-methylcoumarin + H2O
L-Ser + 7-amino-4-methylcoumarin
15% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Tyr 7-amido-4-methylcoumarin + H2O
L-Tyr + 7-amino-4-methylcoumarin
-
fluorogenic substrate
-
-
?
L-Tyr-2-naphthylamide + H2O
L-Tyr + 2-naphthylamine
L-Tyr-7-amido-4-methylcoumarin + H2O
L-Tyr + 7-amino-4-methylcoumarin
about 7% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Val-2-naphthylamide + H2O
L-Val + 2-naphthylamine
-
0.034% activity compared to L-Arg-2-naphthylamide
-
-
?
L-Val-4-nitroanilide + H2O
L-Val + 4-nitroaniline
low activity
-
-
?
L-Val-7-amido-4-methylcoumarin + H2O
L-Val + 7-amino-4-methylcoumarin
about 1% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
Leu-2-naphthylamide + H2O
Leu + 2-naphthylamine
-
-
-
-
?
Leu-4-nitroanilide + H2O
Leu + 4-nitroaniline
Leu-Gly + H2O
Leu + Gly
-
1200% of the activity with Leu-4-nitroanilide
-
?
leukotriene A4 + H2O
L-Arg + leukotriene B4
-
weak in vitro activity
-
-
?
leukotriene A4 + H2O
leukotriene B4 + ?
-
has a residual catalytic ability to hydrolyze leukotriene A4
-
-
?
Lys 4-methylcoumarin 7-amide + H2O
Lys + 7-amino-4-methylcoumarin
-
-
-
-
?
Lys-2-naphthylamide + H2O
Lys + 2-naphthylamine
Lys-4-methylcoumarin 7-amide + H2O
Lys + 7-amino-4-methylcoumarin
-
-
-
-
?
Lys-4-nitroanilide + H2O
Lys + 4-nitroaniline
Lys-7-amido-4-methylcoumarin + H2O
Lys + 7-amino-4-methylcoumarin
-
4.3% of the activity with Arg-7-amido-4-methylcoumarin
-
?
Lys-Ala + H2O
Lys + Ala
-
88% of the activity with Arg-Arg
-
?
Lys-Leu-2-naphthylamide + H2O
Lys + Leu-2-naphthylamide
-
-
-
-
?
Lys-Lys + H2O
Lys + Lys
-
30% of the activity with Arg-Arg
-
?
Met-4-nitroanilide + H2O
Met + 4-nitroaniline
-
40.6% of the activity with Leu-4-nitroanilide
-
?
Met-enkephalin + H2O
?
-
-
-
-
?
N-p-tosyl-Gly-Pro-Lys-p-nitroanilide + H2O
N-p-tosyl-Gly-Pro-Lys + p-nitroaniline
-
-
-
-
?
N-succinyl-Gly-Pro-Leu-Gly-Pro 7-amido-4-methylcoumarin + H2O
N-succinyl-Gly-Pro-Leu-Gly-Pro + 7-amino-4-methylcoumarin
-
fluorogenic substrate
-
-
?
Poly-L-lysine + H2O
?
-
-
-
-
?
thymopentin + H2O
?
-
-
-
-
?
Val-4-nitroanilide + H2O
Val + 4-nitroaniline
-
1.2% of the activity with Leu-4-nitroanilide
-
?
[Arg0]-Met-enkephalin + H2O
Met-enkephalin + de-[Tyr]-Met-enkephalin
i.e. RYGGFM
-
-
?
additional information
?
-
Ala-Ala 4-nitroanilide + H2O
Ala-Ala + 4-nitroaniline
-
-
-
?
Ala-Ala 4-nitroanilide + H2O
Ala-Ala + 4-nitroaniline
-
-
-
?
Arg-4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Arg-4-methylcoumarin 7-amide + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Arg-4-nitroanilide + H2O
Arg + 4-nitroaniline
-
2.5% of the activity with Leu-4-nitroanilide
-
?
Arg-4-nitroanilide + H2O
Arg + 4-nitroaniline
-
as active as Arg-7-amido-4-methylcoumarin
-
?
Arg-4-nitroanilide + H2O
Arg + 4-nitroaniline
-
-
?
Arg-7-amido-4-methylcoumarin + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
Arg-7-amido-4-methylcoumarin + H2O
Arg + 7-amino-4-methylcoumarin
-
-
-
?
Arg-peptides + H2O
?
-
-
-
-
?
Arg-peptides + H2O
?
-
or Lys-peptides, metabolism of kinin
-
-
?
Arg-peptides + H2O
?
-
attribution to inflammatory and wound healing processes
-
-
?
Arg-peptides + H2O
?
-
takes part in later stages of protein degradation in chloroplasts
-
-
?
Arg-peptides + H2O
?
-
-
-
-
?
Arg-peptides + H2O
?
-
-
-
-
?
Arg-Phe + H2O
Arg + Phe
-
35% of the activity with Arg-Arg
-
?
Arg-Phe + H2O
Arg + Phe
-
-
?
Arg-Pro + H2O
Arg + Pro
-
-
?
Arg-Pro + H2O
Arg + Pro
-
-
?
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg + H2O
Arg + Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
i.e. bradykinin
-
?
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg + H2O
Arg + Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg
i.e. bradykinin
-
?
Gly-2-naphthylamide + H2O
Gly + 2-naphthylamine
-
1% activity compared to L-Lys-2-naphthylamide
-
-
?
Gly-2-naphthylamide + H2O
Gly + 2-naphthylamine
-
less than 0.02% activity compared to L-Arg-2-naphthylamide
-
-
?
Gly-Phe 4-nitroanilide + H2O
Gly-Phe + 4-nitroaniline
-
-
-
?
Gly-Phe 4-nitroanilide + H2O
Gly-Phe + 4-nitroaniline
-
-
-
?
L-Ala-2-naphthylamide + H2O
L-Ala + 2-naphthylamine
-
-
-
-
?
L-Ala-2-naphthylamide + H2O
L-Ala + 2-naphthylamine
-
-
-
-
?
L-Ala-2-naphthylamide + H2O
L-Ala + 2-naphthylamine
-
0.1% activity compared to L-Arg-2-naphthylamide
-
-
?
L-Ala-2-naphthylamide + H2O
L-Ala + 2-naphthylamine
-
83% activity compared to L-Lys-2-naphthylamide
-
-
?
L-Ala-4-nitroanilide + H2O
L-Ala + 4-nitroaniline
low activity
-
-
?
L-Ala-4-nitroanilide + H2O
L-Ala + 4-nitroaniline
-
-
-
-
?
L-Ala-4-nitroanilide + H2O
L-Ala + 4-nitroaniline
-
-
-
-
?
L-Ala-7-amido-4-methylcoumarin + H2O
L-Ala + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
L-Ala-7-amido-4-methylcoumarin + H2O
L-Ala + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Ala-7-amido-4-methylcoumarin + H2O
L-Ala + 7-amino-4-methylcoumarin
about 2% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Ala-7-amido-4-methylcoumarin + H2O
L-Ala + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-(Met)enkephalin + H2O
L-Arg + (Met)enkephalin
-
-
-
?
L-Arg-(Met)enkephalin + H2O
L-Arg + (Met)enkephalin
-
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
35982, 35986, 35991, 35998, 36000, 664535, 665109, 665836, 666534, 678547, 678924, 681632, 731369 -
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
100% activity
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
17% activity compared to L-Lys-2-naphthylamide
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-2-naphthylamide + H2O
L-Arg + 2-naphthylamine
-
-
-
-
?
L-Arg-4-nitroanilide + H2O
L-Arg + 4-nitroaniline
best substrate
-
-
?
L-Arg-4-nitroanilide + H2O
L-Arg + 4-nitroaniline
-
-
-
-
?
L-Arg-4-nitroanilide + H2O
L-Arg + 4-nitroaniline
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
100% activity
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
high activity
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
Corycaeus anglicus
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
100% activity
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
100% activity
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Arg-7-amido-4-methylcoumarin + H2O
L-Arg + 7-amino-4-methylcoumarin
-
best substrate
-
-
?
L-Arg-p-nitroanilide + H2O
L-Arg + p-nitroaniline
-
-
-
-
?
L-Arg-p-nitroanilide + H2O
L-Arg + p-nitroaniline
-
-
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
-
-
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
-
31% activity compared to L-Lys-2-naphthylamide
-
-
?
L-Leu-4-nitroanilide + H2O
L-Leu + 4-nitroaniline
-
-
-
?
L-Leu-4-nitroanilide + H2O
L-Leu + 4-nitroaniline
-
-
-
-
?
L-Leu-7-amido-4-methylcoumarin + H2O
L-Leu + 7-amino-4-methylcoumarin
28% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Leu-7-amido-4-methylcoumarin + H2O
L-Leu + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Leu-7-amido-4-methylcoumarin + H2O
L-Leu + 7-amino-4-methylcoumarin
about 1% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Leu-7-amido-4-methylcoumarin + H2O
L-Leu + 7-amino-4-methylcoumarin
-
-
-
-
?
L-Lys-(Met)enkephalin + H2O
L-Lys + (Met)enkephalin
-
-
-
?
L-Lys-(Met)enkephalin + H2O
L-Lys + (Met)enkephalin
-
-
-
-
?
L-Lys-2-naphthylamide + H2O
L-Lys + 2-naphthylamine
-
-
-
-
?
L-Lys-2-naphthylamide + H2O
L-Lys + 2-naphthylamine
-
-
-
-
?
L-Lys-2-naphthylamide + H2O
L-Lys + 2-naphthylamine
-
100% activity
-
-
?
L-Lys-2-naphthylamide + H2O
L-Lys + 2-naphthylamine
-
41% activity compared to L-Arg-2-naphthylamide
-
-
?
L-Lys-4-nitroanilide + H2O
L-Lys + 4-nitroaniline
-
-
-
?
L-Lys-4-nitroanilide + H2O
L-Lys + 4-nitroaniline
-
-
-
-
?
L-Lys-4-nitroanilide + H2O
L-Lys + 4-nitroaniline
-
-
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
10% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
about 45% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Lys-7-amido-4-methylcoumarin + H2O
L-Lys + 7-amino-4-methylcoumarin
-
17% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Met-2-naphthylamide + H2O
L-Met + 2-naphthylamine
-
-
-
-
?
L-Met-2-naphthylamide + H2O
L-Met + 2-naphthylamine
-
2% activity compared to L-Lys-2-naphthylamide
-
-
?
L-Met-7-amido-4-methylcoumarin + H2O
L-Met + 7-amino-4-methylcoumarin
19% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Met-7-amido-4-methylcoumarin + H2O
L-Met + 7-amino-4-methylcoumarin
about 1% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Met-7-amido-4-methylcoumarin + H2O
L-Met + 7-amino-4-methylcoumarin
-
no activity with Z-Met-7-amido-4-methylcoumarin
-
-
?
L-Phe-7-amido-4-methylcoumarin + H2O
L-Phe + 7-amino-4-methylcoumarin
about 5% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Phe-7-amido-4-methylcoumarin + H2O
L-Phe + 7-amino-4-methylcoumarin
-
2% activity compared to L-Arg-7-amido-4-methylcoumarin
-
-
?
L-Phe-7-amido-4-methylcoumarin + H2O
L-Phe + 7-amino-4-methylcoumarin
-
low activity
-
-
?
L-Tyr-2-naphthylamide + H2O
L-Tyr + 2-naphthylamine
-
0.171% activity compared to L-Arg-2-naphthylamide
-
-
?
L-Tyr-2-naphthylamide + H2O
L-Tyr + 2-naphthylamine
-
62% activity compared to L-Lys-2-naphthylamide
-
-
?
Leu-4-nitroanilide + H2O
Leu + 4-nitroaniline
-
-
-
?
Leu-4-nitroanilide + H2O
Leu + 4-nitroaniline
7% of the activity with Arg-4-nitroanilide
-
?
Leu-4-nitroanilide + H2O
Leu + 4-nitroaniline
7% of the activity with Arg-4-nitroanilide
-
?
Lys-2-naphthylamide + H2O
Lys + 2-naphthylamine
-
-
-
-
?
Lys-2-naphthylamide + H2O
Lys + 2-naphthylamine
-
-
-
-
?
Lys-2-naphthylamide + H2O
Lys + 2-naphthylamine
-
-
-
-
?
Lys-2-naphthylamide + H2O
Lys + 2-naphthylamine
-
-
-
-
?
Lys-4-nitroanilide + H2O
Lys + 4-nitroaniline
-
3.6% of the activity with Arg-7-amido-4-methylcoumarin
-
?
Lys-4-nitroanilide + H2O
Lys + 4-nitroaniline
5% of the activity with Arg-4-nitroanilide
-
?
additional information
?
-
substrate specificity, 4-nitroanilides of Gly, Glu, Asp, Phe, Pro, and Ala-Pro are poor substrates, overview
-
-
?
additional information
?
-
-
substrate specificity, 4-nitroanilides of Gly, Glu, Asp, Phe, Pro, and Ala-Pro are poor substrates, overview
-
-
?
additional information
?
-
-
no hydrolysis of amino acids with apolar groups, without free alpha-amino group, or anionic amino acids
-
-
?
additional information
?
-
-
the enzyme probably is involved in the final stages of peptide and protein precursor processing and maturation mechanisms via the exopeptidase pathway and thereby in some inflammatory processes and tumour development
-
-
?
additional information
?
-
-
the enzyme from testis preferably removes Arg and/or Lys residues from the N-terminus of various peptides, no activity with substrate possessing Pro at the P1 position
-
-
?
additional information
?
-
no activity with L-Ala-7-amido-4-methylcoumarin, L-Cys-7-amido-4-methylcoumarin, L-Gln-7-amido-4-methylcoumarin, L-Glu-7-amido-4-methylcoumarin, Gly-7-amido-4-methylcoumarin, L-His-7-amido-4-methylcoumarin, L-Ile-7-amido-4-methylcoumarin, L-Phe-7-amido-4-methylcoumarin, L-Pro-7-amido-4-methylcoumarin, L-Thr-7-amido-4-methylcoumarin, L-Trp-7-amido-4-methylcoumarin, L-Tyr-7-amido-4-methylcoumarin, and L-Val-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
-
no activity with L-Ala-7-amido-4-methylcoumarin, L-Cys-7-amido-4-methylcoumarin, L-Gln-7-amido-4-methylcoumarin, L-Glu-7-amido-4-methylcoumarin, Gly-7-amido-4-methylcoumarin, L-His-7-amido-4-methylcoumarin, L-Ile-7-amido-4-methylcoumarin, L-Phe-7-amido-4-methylcoumarin, L-Pro-7-amido-4-methylcoumarin, L-Thr-7-amido-4-methylcoumarin, L-Trp-7-amido-4-methylcoumarin, L-Tyr-7-amido-4-methylcoumarin, and L-Val-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
-
substrate specificity, no activity with benzoyl-Arg-2-naphthylamide, and 2-naphthylamides of Glu, Ser, and Tyr, no activity with Phe-Phe-Ala-2-naphthylamide, Leu-Gly-Gly-4-methoxy-2-naphthylamide, and Gly-Pro-Leu-2-naphthylamide, overview
-
-
?
additional information
?
-
-
substrate specificity, no activity with L-Pro-7-amido-4-methylcoumarin and L-Asp-7-amido-4-methylcoumarin, L-Ser-7-amido-4-methylcoumarin is a poor substrate, overview
-
-
?
additional information
?
-
the enzyme is induced by interferon-gamma, the enzyme can trim the N-terminal extended precursor to antigenic peptides in the endoplasmic reticulum
-
?
additional information
?
-
-
the enzyme is induced by interferon-gamma, the enzyme can trim the N-terminal extended precursor to antigenic peptides in the endoplasmic reticulum
-
?
additional information
?
-
-
the enzyme probably is involved in the final stages of peptide and protein precursor processing and maturation mechanisms via the exopeptidase pathway and thereby in some inflammatory processes and tumour development
-
-
?
additional information
?
-
-
the enzyme from testis preferably removes Arg and/or Lys residues from the N-terminus of various peptides, no activity with substrate possessing Pro at the P1 position
-
-
?
additional information
?
-
-
the enzyme is strictly specific for the removal of N-terminal basic residues from peptides and proteins
-
-
?
additional information
?
-
no activity with L-Cys-7-amido-4-methylcoumarin, L-Asp-7-amido-4-methylcoumarin, and L-Glu-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
-
no activity with L-Cys-7-amido-4-methylcoumarin, L-Asp-7-amido-4-methylcoumarin, and L-Glu-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
the aminopeptidase binding site shares a similar structure to LTA4H (EC 3.3.2.6) at its ligand binding sites
-
-
?
additional information
?
-
-
no activity with Ala-Ala, Ala-Lys, Asp-Ala, Gly-Ala and Leu-Ala. The enzyme exclusively hydrolyzes basic amino acids from the amino termini of peptide substrates. The nature of the amino acid residue at the C-terminus of the dipeptide has an effect on hydrolysis rate. The activity is maximal towards dipeptides with Arg, Lys, or Ala as the C-terminal residue
-
?
additional information
?
-
-
the enzyme probably is involved in the final stages of peptide and protein precursor processing and maturation mechanisms via the exopeptidase pathway and thereby in some inflammatory processes and tumour development
-
-
?
additional information
?
-
-
the enzyme from testis preferably removes Arg and/or Lys residues from the N-terminus of various peptides, no activity with substrate possessing Pro at the P1 position
-
-
?
additional information
?
-
-
the enzyme is strictly specific for the removal of N-terminal basic residues from peptides and proteins
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
the enzyme plays a role in peptide or protein precursor processing, the enzyme expression is up-regulated during ontogenesis
-
-
?
additional information
?
-
-
the enzyme probably is involved in the final stages of peptide and protein precursor processing and maturation mechanisms via the exopeptidase pathway and thereby in some inflammatory processes and tumour development, the enzyme from testis preferably removes Arg and/or Lys residues from the N-terminus of various peptides
-
-
?
additional information
?
-
-
the enzyme probably is involved in the final stages of peptide and protein precursor processing and maturation mechanisms via the exopeptidase pathway and thereby in some inflammatory processes and tumour development, the enzyme from testis preferably removes Arg and/or Lys residues from the N-terminus of various peptides
-
-
?
additional information
?
-
the enzyme catalyzes the N-terminal cleavage of basic residues of peptide or protein substrates
-
-
?
additional information
?
-
-
the enzyme from testis preferably removes Arg and/or Lys residues from the N-terminus of various peptides, no activity with bradykinin, neurotensin precursor and substance P, no activity with substrate possessing Pro at the P1 position
-
-
?
additional information
?
-
-
the enzyme is strictly specific for the removal of N-terminal basic residues from peptides and proteins, no activity with bradykinin, no activity with substrate possessing Pro at the P1 position
-
-
?
additional information
?
-
-
no activity with L-Ala-7-amido-4-methylcoumarin, L-Asn-7-amido-4-methylcoumarin, L-Gln-7-amido-4-methylcoumarin, L-Glu-7-amido-4-methylcoumarin, Gly-7-amido-4-methylcoumarin, L-His-7-amido-4-methylcoumarin, L-Ile-7-amido-4-methylcoumarin, L-Leu-7-amido-4-methylcoumarin, L-Asp-7-amido-4-methylcoumarin, L-Thr-7-amido-4-methylcoumarin, L-Met-7-amido-4-methylcoumarin, L-Trp-7-amido-4-methylcoumarin, L-Ser-7-amido-4-methylcoumarin, L-Tyr-7-amido-4-methylcoumarin, and L-Val-7-amido-4-methylcoumarin
-
-
?
additional information
?
-
-
no activity with L-alpha-Asn-2-naphthylamide, L-Glu-2-naphthylamide, L-Ile-2-naphthylamide, L-Phe-2-naphthylamide, L-Pro-2-naphthylamide, L-Ser-2-naphthylamide, L-Thr-2-naphthylamide, L-Trp-2-naphthylamide, L-Val-2-naphthylamide, and L-Arg-L-Arg-2-naphthylamide
-
-
?
additional information
?
-
-
no detectable activity with L-Asp-2-naphthylamide
-
-
?
additional information
?
-
proteolysis is restricted to peptides with an arginine residue in the N terminus, with cleavage detected only when a hydrophobic or an uncharged residue occupies the second site
-
?
additional information
?
-
-
proteolysis is restricted to peptides with an arginine residue in the N terminus, with cleavage detected only when a hydrophobic or an uncharged residue occupies the second site
-
?
additional information
?
-
the enzyme may serve as a critical factor for arginine acquisition during nutrient stress in vivo and also in the proteolysis of host proteins and peptides during SBE pathology
-
?
additional information
?
-
-
the enzyme may serve as a critical factor for arginine acquisition during nutrient stress in vivo and also in the proteolysis of host proteins and peptides during SBE pathology
-
?
additional information
?
-
proteolysis is restricted to peptides with an arginine residue in the N terminus, with cleavage detected only when a hydrophobic or an uncharged residue occupies the second site
-
?
additional information
?
-
-
proteolysis is restricted to peptides with an arginine residue in the N terminus, with cleavage detected only when a hydrophobic or an uncharged residue occupies the second site
-
?
additional information
?
-
the enzyme may serve as a critical factor for arginine acquisition during nutrient stress in vivo and also in the proteolysis of host proteins and peptides during SBE pathology
-
?
additional information
?
-
-
the enzyme may serve as a critical factor for arginine acquisition during nutrient stress in vivo and also in the proteolysis of host proteins and peptides during SBE pathology
-
?
additional information
?
-
-
substrate specificity, the enzyme prefers Arg or Lys in N-terminal position, no activity with dipeptide-4-nitroanilides, overview
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid
-
1-methyl cyclohexan bestatin
-
i.e. BE15, strong inhibition
2,4-dinitrofluorobenzene
-
-
2,6-pyridinedicarboxylate
-
-
2-Chloroethylphosphonic acid
-
-
3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]-propanoic acid
-
4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
enzyme binding structure, overview
4-chloromercuribenzoate
-
-
5,5 dithiobis(2-nitrobenzoic acid)
-
1 mM, 74.89% enzyme inhibition
5,5'-dithiobis(2-nitrobenzoate)
Ag+
-
complete inhibition at 0.1 mM
Aprotinin
-
34% residual activity at 0.25 mg/ml
apstatin
0.1 mM, 50% inhibition
arginine derivatives
-
with carboxyl or alpha-amino group blocked
Borax-pyruvic acid buffer
-
-
citric acid-sodium citrate buffer
-
-
curcumin
-
non-competitive inhibitor
Cyclopeptide OF49-II
-
from Penicillium regulosum, total synthesis
-
DFP
5 mM, 25% inhibition. 10 mM, 44% inhibition
DX600
-
only blocks human ACE2 activity but not mouse
E-64
-
99% residual activity at 0.1 mM
Glu-pyrrolidide
0.1 mM, 98% inhibition
glutathione
-
high concentration
Gly-Gly
5 mM, 8% inhibition
HgCl2
-
complete inhibition at 1 mM
iodoacetate
-
0.1 mM, complete inactivation
kallidin
-
human peptide hormone, 10 microM, Arg 4-methylcoumarin 7-amide hydrolysis: 73.7% (wild-type enzyme)
L-1-tosylamido-2-phenylethylchloromethylketone
-
-
L-Arg
5 mM, 70% inhibition
L-Arg-2-naphthylamide
-
competitive inhibition of hydrolysis of L-Ala-2-naphthylamide, no inhibition vice versa
L-Lys
5 mM, 28% inhibition
leuhistin
-
40% inhibition at 0.0003 mM, independent on TGF-beta1 activation
mangiferin
-
mixed non-competitive inhibitor
Mg2+
-
slight inhibition at 1 mM
MgCl2
-
0.1 mM MgCl2, 22% inhibition
N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide
-
N-alpha-p-Tosyl-L-lysine
-
-
N-alpha-p-tosyl-L-lysine-chloromethyl ketone
-
specific and irreversible inhibitor
N-[(2S,3R)-3-amino-2-hydroxy-5-methylhexanoyl]-L-valyl-L-valyl-L-aspartic acid
-
-
N-[1-(R,S)-carboxy-3-phenyl propyl] Ala-Ala-Phe-p-aminobenzoate
-
-
Na+
-
NaCl (0.1-100 mM) has an opposite effect on the EGTA-treated KAP apo-enzyme, it inhibits 13% at 0.1 mM and 100% at 100 mM
NEM
-
13% inhibition at 1 mM
nitrobestatin
-
92.3% inhibition at 0.133 mM
o-phenanthroline
-
the native enzyme is inhibited by 76% at 0.5 mM, the recombinant enzyme is inhibited by 80% at 0.5 mM
p-aminophenylmercuric acetate
-
1 mM, 41.27% enzyme inhibition
p-chloromercuribenzene sulfonic acid
-
-
p-hydroxymercuriphenyl sulfonic acid
-
1 mM, 72.22% enzyme inhibition
p-Hydroxymercuriphenylsulfonic acid
-
-
PCMB
2 mM, complete inactivation
Phenylmethanesulfonylfluoride
suberanilohydroxamic acid
enzyme binding structure, overview
-
Substance P
-
human peptide hormone, 100 microM, Arg 4-methylcoumarin 7-amide hydrolysis: 63.8% (wild-type enzyme); human peptide hormone, 10 microM, Arg 4-methylcoumarin 7-amide hydrolysis: 78% (wild-type enzyme)
tert-butyl bestatin
-
i.e. BE17, the BE15 derivative has a dual inhibitory effect of invasion and motility on tumor and endothelial cells
[(2Z)-3-[(7-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
11.7% inhibition at 0.01 mM
[(2Z)-3-[2-(6-methyl-4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
54.8% inhibition at 0.01 mM
[(2Z)-3-[2-(6-nitro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
32.8% inhibition at 0.01 mM
[(2Z)-3-[2-(7-bromo-4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
53.5% inhibition at 0.01 mM
[(2Z)-3-[2-(7-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
65.2% inhibition at 0.01 mM
[(2Z)-3-[2-(7-fluoro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
36.4% inhibition at 0.01 mM
[(2Z)-3-[4-(6-methyl-4-oxo-1,2,3-benzotriazin-3(4H)-yl)butyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
26.0% inhibition at 0.01 mM
[(2Z)-3-[4-(6-nitro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)butyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
22.2% inhibition at 0.01 mM
[(2Z)-3-[4-(7-bromo-4-oxo-1,2,3-benzotriazin-3(4H)-yl)butyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
26.8% inhibition at 0.01 mM
[(2Z)-3-[4-(7-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)butyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
33.7% inhibition at 0.01 mM
[(2Z)-3-[4-(7-fluoro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)butyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
26.0% inhibition at 0.01 mM
[(2Z)-3-[5-(6-methyl-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
52.6% inhibition at 0.01 mM
[(2Z)-3-[5-(6-nitro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
34.1% inhibition at 0.01 mM
[(2Z)-3-[5-(7-bromo-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
78.8% inhibition at 0.01 mM
[(2Z)-3-[5-(7-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
76.1% inhibition at 0.01 mM
[(2Z)-3-[5-(7-fluoro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
54.0% inhibition at 0.01 mM
[(2Z)-3-[6-(5-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
37.8% inhibition at 0.01 mM
[(2Z)-3-[6-(6-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
68.8% inhibition at 0.01 mM
[(2Z)-3-[6-(6-methyl-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
62.5% inhibition at 0.01 mM
[(2Z)-3-[6-(6-nitro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
36.9% inhibition at 0.01 mM
[(2Z)-3-[6-(7-bromo-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
70.6% inhibition at 0.01 mM
[(2Z)-3-[6-(7-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
80.6% inhibition at 0.01 mM
[(2Z)-3-[6-(7-fluoro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
51.7% inhibition at 0.01 mM
[(2Z)-3-[6-(7-methoxy-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
50.3% inhibition at 0.01 mM
[(2Z)-3-[6-(7-nitro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
34.6% inhibition at 0.01 mM
[(2Z)-3-[6-(8-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
37.9% inhibition at 0.01 mM
[(2Z)-4-oxo-3-[(4-oxo-1,2,3-benzotriazin-3(4H)-yl)methyl]-1,3-thiazolidin-2-ylidene]cyanamide
over 10.0% inhibition at 0.01 mM
[(2Z)-4-oxo-3-[2-(4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-1,3-thiazolidin-2-ylidene]cyanamide
30.2% inhibition at 0.01 mM
[(2Z)-4-oxo-3-[2-[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]ethyl]-1,3-thiazolidin-2-ylidene]cyanamide
55.6% inhibition at 0.01 mM
[(2Z)-4-oxo-3-[4-[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]butyl]-1,3-thiazolidin-2-ylidene]cyanamide
41.6% inhibition at 0.01 mM
[(2Z)-4-oxo-3-[5-[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]pentyl]-1,3-thiazolidin-2-ylidene]cyanamide
50.1% inhibition at 0.01 mM
[(2Z)-4-oxo-3-[6-[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]hexyl]-1,3-thiazolidin-2-ylidene]cyanamide
60.1% inhibition at 0.01 mM
[(2Z)-4-oxo-3-[[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]methyl]-1,3-thiazolidin-2-ylidene]cyanamide
15.8% inhibition at 0.01 mM
1,10-phenanthroline
-
-
1,10-phenanthroline
complete inhibition, reversible by Zn2+
1,10-phenanthroline
-
activity restored by Co2+
1,10-phenanthroline
effective
1,10-phenanthroline
-
reversible by Zn2+
1,10-phenanthroline
-
34% residual activity at 1 mM
1,10-phenanthroline
-
complete inhibition at 1 mM
1,10-phenanthroline
-
68.5% inhibition at 5 mM
2-mercaptoethanol
-
-
2-mercaptoethanol
-
enzyme II
3,4-dichloroisocoumarin
-
0.1 mM, 12% inhibition. 1.0 mM, 16% inhibition
3,4-dichloroisocoumarin
-
-
3,4-dichloroisocoumarin
2 mM, 38% inhibition
5,5'-dithiobis(2-nitrobenzoate)
-
-
5,5'-dithiobis(2-nitrobenzoate)
-
-
actinonin
-
40% inhibition at 0.0003 mM, independent on TGF-beta1 activation
amastatin
-
amastatin
-
50-70% inhibition at 0.0003 mM, dependent on TGF-beta1 activation
amastatin
1 mM, 11% inhibition
amino acids
-
-
Arg
-
noncompetitive
arphamenine A
complete inhibition at 0.1 mM
arphamenine A
-
aminopeptidase B-specific inhibitor
arphamenine A
-
the native enzyme is completely inhibited at 0.001 mM, the recombinant enzyme is completely inhibited at 0.001 mM
arphamenine A
-
complete inhibition at 0.1 mM
Arphamenine B
-
-
Arphamenine B
aminopeptidase B-specific inhibitor
Arphamenine B
-
the native enzyme is completely inhibited at 0.001 mM, the recombinant enzyme is completely inhibited at 0.001 mM
bestatin
-
-
bestatin
complete inhibition at 0.1 mM
bestatin
-
strong inhibition
bestatin
orally applicated inhibits the melanoma cell-induced angiogenesis in mice air sacs
bestatin
-
the native enzyme is completely inhibited at 0.05 mM, the recombinant enzyme is completely inhibited at 0.1 mM
bestatin
-
complete inhibition at 0.1 mM
bestatin
-
highly sensitive to bestatin
bestatin
1 mM, 32% inhibition
bestatin
-
84.8% inhibition at 0.3 mM
beta-mercaptoethanol
4% inhibition at 10 mM
beta-mercaptoethanol
-
20% inhibition at 10 mM
Ca2+
-
16% inhibition at 1 mM, 24% inhibition at 10 mM
Ca2+
-
0.1 mM CaCl2, 19% inhibition
Ca2+
-
19% inhibition at 1 mM
Ca2+
-
slight inhibition at 1 mM
Cd2+
-
-
Cd2+
-
inhibits Cd2+-saturated enzyme, inhibits the Ni2+-saturated enzyme
Cd2+
-
complete inhibition at 1 mM
Co2+
62% inhibition at 1 mM
Co2+
-
inhibits Cd2+-saturated enzyme, inhibits the Ni2+-saturated enzyme
Co2+
-
0.1 mM CoCl2, 23% inhibition
Co2+
-
45% inhibition at 1 mM
Co2+
-
76% inhibition at 1 mM
Co2+
-
strong inhibition at 1 mM
Cu2+
-
84% inhibition at 0.1 mM
Cu2+
-
0.1 mM CuCl2, complete inhibition
Cu2+
-
complete inhibition at 1 mM
Cu2+
-
complete inhibition at 1 mM
cysteine
21% inhibition at 1 mM
cysteine
-
15% inhibition at 1 mM
dithiothreitol
33% inhibition at 10 mM
dithiothreitol
-
54% inhibition at 10 mM
DTT
-
1 mM, complete inhibition of enzyme activity
DTT
-
25% inhibition at 1 mM, complete inhibition at 10 mM
DTT
-
9% inhibition at 1 mM
E64
48% inhibition at 0.01 mM
E64
-
12% inhibition at 0.01 mM
EDTA
12% inhibition at 1 mM
EDTA
-
1 mM, 42.33% enzyme inhibition
EDTA
-
complete inhibition at 1-10 mM
EDTA
-
complete loss of activity after dialysis with EDTA
EDTA
-
the native enzyme is inhibited by 95% at 10 mM, the recombinant enzyme is inhibited by 71% at 10 mM
EDTA
-
54% inhibition at 1 mM
EDTA
-
61% residual activity at 1 mM
EDTA
-
90% inhibition at 1 mM
EGTA
-
-
EGTA
-
complete inhibition at 1 mM
Fe2+
-
-
Fe2+
-
inhibits the Ni2+-saturated enzyme
Hg2+
-
complete inhibition at 0.1 mM
Hg2+
-
0.1 mM HgCl2, complete inhibition
Hg2+
-
complete inhibition at 1 mM
Hg2+
-
complete inhibition at 1 mM
iodoacetamide
5 mM, 9% inhibition
iodoacetamide
-
16% inhibition at 1 mM
leupeptin
-
5% inhibition at 0.01 mM
Lys
-
noncompetitive
MLN-4760
-
MLN-4760 inhibits both human and mouse ACE2
MLN-4760
-
MLN-4760 inhibits both human and mouse ACE2
Mn2+
-
complete inhibition at 10 mM
Mn2+
-
82% inhibition at 1 mM
Mn2+
-
strong inhibition at 1 mM
N-ethylmaleimide
44% inhibition at 0.1 mM
N-ethylmaleimide
-
the native enzyme is inhibited by 45% at 1 mM, the recombinant enzyme is inhibited by 71% at 1 mM
N-ethylmaleimide
-
21% inhibition at 0.1 mM
NaI
-
-
Ni2+
75% inhibition at 1 mM
Ni2+
-
inhibits Cd2+-saturated enzyme
Ni2+
-
63% inhibition at 1 mM
Ni2+
-
complete inhibition at 1 mM
Ni2+
-
strong inhibition at 1 mM
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
Pb2+
-
-
Pb2+
-
84% inhibition at 1 mM
pefabloc
5 mM, 60% inhibition. 10 mM 69% inhibition
pepstatin
-
93% residual activity at 0.1 mM
pepstatin
-
5% inhibition at 0.01 mM
Phenylmethanesulfonylfluoride
10% inhibition at 0.1 mM
Phenylmethanesulfonylfluoride
-
1% inhibition at 0.1 mM
Phenylmethanesulfonylfluoride
-
45% residual activity at 0.5 mM
PMSF
-
14% inhibition at 1 mM
puromycin
-
-
puromycin
10% inhibition at 0.1 mM
puromycin
-
1% inhibition at 0.1 mM
SDS
5%, 96% inhibition
Urea
2 M, 18% inhibition
Zn2+
complete inhibition at 0.1 mM
Zn2+
-
complete inhibition at 0.1-10 mM
Zn2+
-
inhibits Cd2+-saturated enzyme, inhibits the Ni2+-saturated enzyme
Zn2+
-
0.1 mM ZnCl2, 82% inhibition
Zn2+
-
99% inhibition at 0.1 mM
Zn2+
-
80% inhibition at 1 mM
Zn2+
-
Zn2+ inhibits AP-B reversibly at micromolar concentrations (0.005-0.05 mM), AP-B with 0.25 Zn2+ becomes susceptible to degradation by trypsin suggesting that Zn2+ alters enzyme conformation, complete inhibition occurs at 0.050-0.080 mM
Zn2+
-
complete inhibition at 1 mM
ZnCl2
-
-
ZnCl2
-
96% inhibition at 1 mM
additional information
-
no inhibition at 0.1 mM by Mg2+
-
additional information
EDTA has no effect up to 1 mM
-
additional information
-
EDTA has no effect up to 1 mM
-
additional information
-
inhibitory potency of bestatin and derivatives on enzyme activity, umbilical vein endothelial cell vessel formation, and cell invasion and migration, overview
-
additional information
synthesis and evaluation of a series of 1,2,3-benzotriazin-4-one derivatives as inhibitors of leukotriene A4 hydrolase aminopeptidase activity of the enzyme in vitro, overview. Molecular docking and structure-activity relationship of the inhibitors, IC50 values for cytotoxic effects on THP-1 cells
-
additional information
drug repurposing of histone deacetylase (HDAC) inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis, overview. Analysis of potential inhibitors of LTA4H across a panel of 18 HDAC inhibitors, using enzymatic assay, thermofluor assay, and X-ray crystallographic investigation. Detailed mechanisms of down-regulation of proinflammatory cytokines by SAHA or M344 are determined in vivo. Cotreatment of N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide and (S)-2-((2S,3R)-3-amino-2-hydroxy-4-phenylbutanamido)-4-methylpentanoic acid synergistically represses the migration of neutrophil and LTB4-induced neutrophil migration is not affected by these treatments. Molecular modeling of HDAC inhibitors against LTA4H hydrolase and aminopeptidase
-
additional information
-
no or poor inhibition of L-Arg-2-naphthylamide hydrolysis by puromycin at 1 mM, aprotinin, pepstatin A, E64, chymostatin, imipramine, phosphoramidon, lisinopril, and apstatin
-
additional information
-
no inhibition by PMSF, pepstatin, and aprotinin
-
additional information
-
no inhibition by puromycin
-
additional information
-
no inhibition by PMSF, pepstatin, and aprotinin
-
additional information
-
not affected by phenylmethylsulfonylfluoride
-
additional information
-
insensitive to L-Arg-hydroxamate, L-Lys-hydroxamate, puromycin, and amastatin
-
additional information
-
At 0.2 mM, no significant inhibitory effect is observed with caffeic, chlorogenic, ferulic, salicylic and sinapic acids as well as with resveratrol
-
additional information
-
no inhibition by phosphoramidon, E64, antipaine, and TLCK
-
additional information
-
no inhibition by pepstatin
-
additional information
-
no inhibition by epibestatin, and by E64, chymostatin, leupeptin, and antipain
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00006 - 0.000077
1,10-phenanthroline
0.0003
4-(dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide
Homo sapiens
pH and temperature not specified in the publication
0.01
abexinostat
Homo sapiens
above, pH and temperature not specified in the publication
0.00000316 - 0.00000402
arphamenine A
0.0000007 - 0.00000155
Arphamenine B
0.01
belinostat
Homo sapiens
above, pH and temperature not specified in the publication
0.00000349 - 0.0005
bestatin
0.01
CUDC-101
Homo sapiens
above, pH and temperature not specified in the publication
0.01
entinostat
Homo sapiens
above, pH and temperature not specified in the publication
0.01
givinostat
Homo sapiens
above, pH and temperature not specified in the publication
0.01
JNJ-26481585
Homo sapiens
above, pH and temperature not specified in the publication
0.01
mocetinostat
Homo sapiens
above, pH and temperature not specified in the publication
0.01
N-(6-(2-aminophenylamino)-6-oxyhexyl)-4-methylbenzamide
Homo sapiens
above, pH and temperature not specified in the publication
0.01
panobinostat
Homo sapiens
above, pH and temperature not specified in the publication
0.01
pracinostat
Homo sapiens
above, pH and temperature not specified in the publication
0.01
resminostat
Homo sapiens
above, pH and temperature not specified in the publication
0.01
rocilinostat
Homo sapiens
above, pH and temperature not specified in the publication
0.0044
scriptaid
Homo sapiens
pH and temperature not specified in the publication
0.00167
suberanilohydroxamic acid
Homo sapiens
pH and temperature not specified in the publication
-
0.01
trichostatin A
Homo sapiens
above, pH and temperature not specified in the publication
0.01
tubacin
Homo sapiens
above, pH and temperature not specified in the publication
0.01
Valproate
Homo sapiens
above, pH and temperature not specified in the publication
0.00000391 - 0.00000592
ZnCl2
7.77
[(2Z)-3-[2-(6-methyl-4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
7.9
[(2Z)-3-[2-(7-bromo-4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
7.39
[(2Z)-3-[2-(7-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)ethyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
12.09
[(2Z)-3-[5-(6-methyl-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
1.71
[(2Z)-3-[5-(7-bromo-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
2.17
[(2Z)-3-[5-(7-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
7.9
[(2Z)-3-[5-(7-fluoro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)pentyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
3.87
[(2Z)-3-[6-(6-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
7.19
[(2Z)-3-[6-(6-methyl-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
6.82
[(2Z)-3-[6-(7-bromo-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
1.3
[(2Z)-3-[6-(7-chloro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
12.27
[(2Z)-3-[6-(7-fluoro-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
13.53
[(2Z)-3-[6-(7-methoxy-4-oxo-1,2,3-benzotriazin-3(4H)-yl)hexyl]-4-oxo-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
10.11
[(2Z)-4-oxo-3-[2-[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]ethyl]-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
14.89
[(2Z)-4-oxo-3-[5-[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]pentyl]-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
7.7
[(2Z)-4-oxo-3-[6-[4-oxo-6-(trifluoromethyl)-1,2,3-benzotriazin-3(4H)-yl]hexyl]-1,3-thiazolidin-2-ylidene]cyanamide
Homo sapiens
pH 7.5, 22°C
0.00006
1,10-phenanthroline
Homo sapiens
-
pH 7.4, 37°C, mutant Q169N
0.000077
1,10-phenanthroline
Homo sapiens
-
pH 7.4, 37°C, wild-type
0.00000316
arphamenine A
Homo sapiens
-
pH 7.4, 37°C, mutant Q169N
0.00000373
arphamenine A
Homo sapiens
-
pH 7.4, 37°C, wild-type
0.00000402
arphamenine A
Homo sapiens
wild type enzyme, at pH 7.4 and 37°C
0.0000007
Arphamenine B
Homo sapiens
wild type enzyme, at pH 7.4 and 37°C
0.00000072
Arphamenine B
Homo sapiens
-
pH 7.4, 37°C, wild-type
0.00000155
Arphamenine B
Homo sapiens
-
pH 7.4, 37°C, mutant Q169N
0.00000349
bestatin
Homo sapiens
-
pH 7.4, 37°C, wild-type
0.00000382
bestatin
Homo sapiens
wild type enzyme, at pH 7.4 and 37°C
0.000289
bestatin
Homo sapiens
-
pH 7.4, 37°C, mutant Q169N
0.0005
bestatin
Homo sapiens
pH 7.5, 22°C
0.00000391
ZnCl2
Homo sapiens
-
pH 7.4, 37°C, wild-type
0.00000592
ZnCl2
Homo sapiens
-
pH 7.4, 37°C, mutant Q169N
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Sharma, A.; Padwal-Desai, S.R.; Ninjoor, V.
Intracellular hydrolases of Aspergillus parasiticus and Aspergillus flavus
Biochem. Biophys. Res. Commun.
159
464-471
1989
Aspergillus flavus, Aspergillus parasiticus
brenda
Mendz, G.L.; McCall, M.N.; Kuchel, P.W.
Characterization of leukocyte enzymes involved in the release of amino acids in incubated blood cell lysates
J. Biol. Chem.
264
2108-2117
1989
Homo sapiens
brenda
Schmidt, U.; Weller, D.; Holder, A.; Lieberknecht, A.
Total synthesis of OF4949-III, a natural inhibitor of aminopeptidase B from Ehrlich ascites carcinoma cells
Tetrahedron Lett.
29
3227-3230
1988
Mus musculus
-
brenda
Lauffart, B.; Mantle, D.
Rationalization of aminopeptidase activities in human skeletal muscle soluble extract
Biochim. Biophys. Acta
956
300-306
1988
Homo sapiens
brenda
Harbeson, S.L.; Rich, D.H.
Inhibition of arginine aminopeptidase by bestatin and arphamenine analogues. Evidence for a new mode of binding to aminopeptidases
Biochemistry
27
7301-7310
1988
Rattus norvegicus
brenda
Lauffart, B.; McDermott, J.; Jones, P.; Mantle, D.
Amino acid inhibition of aminopeptidases purified from human cerebral cortex
Biochem. Soc. Trans.
16
849-850
1988
Homo sapiens
-
brenda
Ishiura, S.; Yamamoto, T.; Yamamoto, M.; Nojima, M.; Aoyagi, T.; Sugita, H.
Human skeletal muscle contains two major aminopeptidases: an anion-activated aminopeptidase B and an aminopeptidase M-like enzyme
J. Biochem.
102
1023-1031
1987
Homo sapiens
brenda
Ocain, T.D.; Rich, D.H.
L-Lysinethiol: a subnanomolar inhibitor of aminopeptidase B
Biochem. Biophys. Res. Commun.
145
1038-1042
1987
Rattus norvegicus
brenda
Hiraoka, B.Y.
Immunochemical properties and intracellular localization of two molecular forms of arginine aminopeptidase in Streptococcus mitis ATCC 9811
Biochim. Biophys. Acta
841
166-172
1985
Streptococcus mitis
brenda
Blahovec, J.; Bartik, M.; Kasafirek, E.
Isolation and partial characterization of bovine liver aminopeptidase B
Collect. Czech. Chem. Commun.
50
1249-1257
1985
Bos taurus
-
brenda
Chan, S.A.T.; Toursarkissian, K.; Sweeny, J.P.; Jones, T.H.D.
Dipeptidyl-aminopeptidases and aminopeptidases in Dictyostelium discoideum
Biochem. Biophys. Res. Commun.
127
962-968
1985
Dictyostelium discoideum
brenda
Mantle, D.; Lauffart, B.; Pennington, R.J.T.
Purification and partial characterization of arginine aminopeptidases from human skeletal muscle
Biochem. Soc. Trans.
12
826-827
1984
Homo sapiens
-
brenda
Hiraoka, B.Y.; Fukasawa, K.; Harada, M.
Purification and characterization of two novel arginine aminopeptidases from Streptococcus mitis ATCC 9811
J. Biochem.
94
1201-1208
1983
Streptococcus mitis
brenda
Matsuzawa, T.; Hatsugai, M.
Effect of age on the activity of rat testicular arginine-aminopeptidase
Experientia
39
388-389
1983
Rattus norvegicus
brenda
Soederling, E.; Mkinen, K.K.
Modification of the Cl- -activated arginine aminopeptidases from rat liver and human erythrocytes: a comparative study
Arch. Biochem. Biophys.
220
11-21
1983
Homo sapiens, Rattus norvegicus
brenda
Soederling, E.
Substrate specificities of Cl- -activated arginine aminopeptidases from human and rat origin
Arch. Biochem. Biophys.
220
1-10
1983
Homo sapiens, Rattus norvegicus
brenda
Soederling, E.
Effect of Cl- on the function of the Cl- -activated arginine aminopeptidase purified from human erythrocytes
Arch. Biochem. Biophys.
216
105-115
1982
Homo sapiens
brenda
Kawata, S.; Takayama, S.; Ninimiya, K.; Makisumi, S.
Purification and some properties of porcine liver aminopeptidase B
J. Biochem.
88
1025-1032
1980
Sus scrofa
brenda
Kawata, S.; Takayama, S.; Ninomiya, K.; Makisumi, S.
Porcine liver aminopeptidase B. Substrate specificity and inhibition by amino acids
J. Biochem.
88
1601-1605
1980
Sus scrofa
brenda
Knuuttila, M.; Virtanen, K.; Soederling, E.; Maekinen, K.K.
A chloride-activated aminopeptidase in rat inflammatory exudate: properties and evidence of the origin of the enzyme
Biochem. Biophys. Res. Commun.
81
374-381
1978
Rattus norvegicus
brenda
Aoyagi, T.; Suda, H.; Nagai, M.; Ogawa, K.; Suzuki, J.; Takeuchi, T.; Umezawa, H.
Aminopeptidase activities on the surface of mammalian cells
Biochim. Biophys. Acta
452
131-143
1976
Canis lupus familiaris, Platyrrhini, Rattus norvegicus
brenda
Suda, H.; Aoyagi, T.; Takeuchi, T.; Umezawa, H.
Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer
Arch. Biochem. Biophys.
177
196-200
1976
Rattus norvegicus
brenda
Mkinen, P.L.; Mkinen, K.K.
Fractionation and properties of aminopeptidase B during purification and storage
Int. J. Pept. Protein Res.
4
241-255
1972
Rattus norvegicus
brenda
Maekinen, K.K.
Evidence for the aggregation of aminopeptidase B during storage and breakdown of the aggregate by substrate and serum albumin
Biochim. Biophys. Acta
271
413-418
1972
Rattus norvegicus
brenda
Maekinen, K.K.; Maekinen, P.L.
Evidence on erythrocyte aminopeptidase B
Int. J. Pept. Protein Res.
111
41-47
1971
Rattus norvegicus
-
brenda
Maekinen, K.K.; Paunio, K.U.
Demonstration of aminopeptidase B in human periodontal tissues
Acta Chem. Scand.
24
1103-1104
1970
Homo sapiens
brenda
Maekinen, P.L.; Raekallio, J.; Maekinen, K.K.
On the localization of aminopeptidase B and separation of its two molecular forms by automated recycling chromatography
Acta Chem. Scand.
24
1101-1102
1970
Rattus norvegicus
brenda
Maekinen, K.K.; Hopsu-Havu, V.K.
The active centre of aminopeptidase B. I. The effects of various chemical reagents
Enzymologia
32
333-346
1967
Rattus norvegicus
brenda
Maekinen, K.K.; Hopsu-Havu, V.K.
The active centre of aminopeptidase B. II. Kinetic studies
Enzymologia
32
347-363
1967
Rattus norvegicus
brenda
Hopsu, V.K.; Maekinen, K.K.; Glenner, G.G.
Purification of a mammalian peptidase selective for N-terminal arginine and lysine residues: aminopeptidase B
Arch. Biochem. Biophys.
114
557-566
1966
Rattus norvegicus
brenda
Hopsu-Havu, V.K.; Maekinen, K.K.
A simplified method for purification of rat liver aminopeptidase B
Arch. Biochem. Biophys.
118
257-258
1967
Rattus norvegicus
-
brenda
Hopsu, V.K.; Maekinen, K.K.; Glenner, G.G.
Characterization of aminopeptidase B: substrate specificity and affector studies
Arch. Biochem. Biophys.
114
567-575
1966
Rattus norvegicus
brenda
McDonald, J.K.; Barrett, A.J.
Soluble arginyl aminopeptidase
Mammalian Proteases, Academic Press
2
48-55
1986
Homo sapiens, Rattus norvegicus, Sus scrofa
-
brenda
Cadel, S.; Pierotti, A.R.; Foulon, T.; Creminon, C.; Barre, N.; Segretain, D.; Cohen, P.
Aminopeptidase B in the rat testes: isolation, functional properties and cellular localization in the seminiferous tubules
Mol. Cell. Endocrinol.
110
149-160
1995
Rattus norvegicus
brenda
Cadel, S.; Foulon, T.; Viron, A.; Balogh, A.; Midol-Monnet, S.; Noel, N.; Cohen, P.
Aminopeptidase B from the rat testis is a bifunctional enzyme structurally related to leukotriene-A4 hydrolase
Proc. Natl. Acad. Sci. USA
94
2963-2968
1997
Rattus norvegicus (O09175)
brenda
Cook, M.; Adam, Z.
Purification and characterization of an arginyl peptidase from the chloroplast stroma of pea seedlings
Plant Physiol. Biochem.
35
163-168
1997
Pisum sativum
-
brenda
Toldra, F.; Falkous, G.; Flores, M.; Mantle, D.
Comparison of aminopeptidase inhibition by amino acids in human and porcine skeletal muscle tissues in vitro
Comp. Biochem. Physiol. B
115
445-450
1996
Homo sapiens, Sus scrofa
-
brenda
Fukasawa, K.M.; Fukasawa, K.; Kanai, M.; Fujii, S.; Harada, M.
Molecular cloning and expression of rat liver aminopeptidase B
J. Biol. Chem.
271
30731-30735
1996
Homo sapiens, Rattus norvegicus
brenda
Yamada, M.; Sukenaga, Y.; Fujii, H.; Abe, F.; Takeuchi, T.
Purification and characterization of a ubenimex (Bestatin)-sensitive aminopeptidase B-like enzyme from K562 human chronic myeloid leukemia cells
FEBS Lett.
342
53-56
1994
Homo sapiens
brenda
Belbacene, N.; Mari, B.; Rossi, B.; Auberger, P.
Characterization and purification of T lymphocyte aminopeptidase B: a putative marker of T cell activation
Eur. J. Immunol.
23
1948-1955
1993
Homo sapiens
brenda
Nagata, Y.; Mizutani, S.; Nomura, S.; Kurauchi, O.; Kasugai, M.; Tomoda, Y.
Purification and properties of human placental aminopeptidase B
Enzyme
45
165-173
1991
Homo sapiens
brenda
Floderus, E.; Linder, L.E.; Sund, M.S.
Characterization of membrane-associated arginine aminopeptidase in Streptococcus sanguis 903
Curr. Microbiol.
21
145-149
1990
Streptococcus sanguinis, Streptococcus sanguinis 903
-
brenda
Herranz, R.; Garcia-Lopez, M.T.; Perez, C.
Synergistic inhibition of aminopeptidase B by penicillamine or cysteine and metallic salts
Arch. Pharm.
324
239-241
1991
Mus musculus
brenda
Flores, M.; Aristoy, M.C.; Toldra, F.
Feedback inhibition of porcine muscle alanyl and arginyl aminopeptidases in cured meat products
J. Agric. Food Chem.
46
4982-4986
1998
Sus scrofa
brenda
Sanz, Y.; Toldra, F.
Purification and characterization of an arginine aminopeptidase from Lactobacillus sakei
Appl. Environ. Microbiol.
68
1980-1987
2002
Latilactobacillus sakei
brenda
Suzuki, H.; Kamatani, S.; Kumagai, H.
Purification and characterization of aminopeptidase B from Escherichia coli K-12
Biosci. Biotechnol. Biochem.
65
1549-1558
2001
Escherichia coli
brenda
Goldstein, J.M.; Nelson, D.; Kordula, T.; Mayo, J.A.; Travis, J.
Extracellular arginine aminopeptidase from Streptococcus gordonii FSS2
Infect. Immun.
70
836-843
2002
Streptococcus gordonii (Q938E9), Streptococcus gordonii, Streptococcus gordonii FSS2 (Q938E9), Streptococcus gordonii FSS2
brenda
Tanioka, T.; Hattori, A.; Masuda, S.; Nomura, Y.; Nakayama, H.; Mizutani, S.; Tsujimoto, M.
Human leukocyte-derived arginine aminopeptidase. The third member of the oxytocinase subfamily of aminopeptidases
J. Biol. Chem.
278
32275-32283
2003
Homo sapiens (Q6P179), Homo sapiens
brenda
Huston, A.L.; Methe, B.; Deming, J.W.
Purification, characterization, and sequencing of an extracellular cold-active aminopeptidase produced by marine psychrophile Colwellia psychrerythraea strain 34H
Appl. Environ. Microbiol.
70
3321-3328
2004
Colwellia psychrerythraea
brenda
Saitoh, Y.; Koizumi, K.; Minami, T.; Sekine, K.; Sakurai, H.; Saiki, I.
A derivative of aminopeptidase inhibitor (BE15) has a dual inhibitory effect of invasion and motility on tumor and endothelial cells
Biol. Pharm. Bull.
29
709-712
2006
Homo sapiens
brenda
Petrov, V.V.; Fagard, R.H.; Lijnen, P.J.
Arginine-aminopeptidase in rat cardiac fibroblastic cells participates in angiotensin peptide turnover
Cardiovasc. Res.
61
724-735
2004
Rattus norvegicus
brenda
Piesse, C.; Cadel, S.; Gouzy-Darmon, C.; Jeanny, J.C.; Carriere, V.; Goidin, D.; Jonet, L.; Gourdji, D.; Cohen, P.; Foulon, T.
Expression of aminopeptidase B in the developing and adult rat retina
Exp. Eye Res.
79
639-648
2004
Rattus norvegicus (O09175)
brenda
Berthonneau, J.; Rodier, M.H.; El Moudni, B.; Jacquemin, J.L.
Toxoplasma gondii: Purification and characterization of an immunogenic metallopeptidase
Exp. Parasitol.
95
158-162
2000
Toxoplasma gondii
brenda
Mercado-Flores, Y.; Noriega-Reyes, Y.; Ramirez-Zavala, B.; Hernandez-Rodriguez, C.; Villa-Tanaca, L.
Purification and characterization of aminopeptidase (pumAPE) from Ustilago maydis
FEMS Microbiol. Lett.
234
247-253
2004
Ustilago maydis
brenda
Fundoiano-Hershcovitz, Y.; Rabinovitch, L.; Shulami, S.; Reiland, V.; Shoham, G.; Shoham, Y.
The ywad gene from Bacillus subtilis encodes a double-zinc aminopeptidase
FEMS Microbiol. Lett.
243
157-163
2005
Bacillus subtilis (P25152), Bacillus subtilis
brenda
Foulon, T.; Cadel, S.; Piesse, C.; Cohen, P.
Aminopeptidase B
Handbook of Proteolytic Enzymes (Barrett, J. ; Rawlings, N. D. ; Woessner, J. F. , eds) Academic Press
1
328-332
2004
Homo sapiens, Mus musculus, Rattus norvegicus
-
brenda
Agirregoitia, N.; Laiz-Carrion, R.; Varona, A.; Rio, M.P.; Mancera, J.M.; Irazusta, J.
Distribution of peptidase activity in teleost and rat tissues
J. Comp. Physiol. B
175
433-444
2005
Oncorhynchus mykiss, Rattus norvegicus, Sparus aurata
brenda
Millership, J.J.; Chappell, C.; Okhuysen, P.C.; Snowden, K.F.
Characterization of aminopeptidase activity from three species of microsporidia: Encephalitozoon cuniculi, Encephalitozoon hellem, and Vittaforma corneae
J. Parasitol.
88
843-848
2002
Vittaforma corneae
brenda
Ohishi, K.; Yamamoto, T.; Tomofuji, T.; Tamaki, N.; Watanabe, T.
Isolation and characterization of aminopeptidase from Capnocytophaga granulosa ATCC 51502
Oral Microbiol. Immunol.
20
67-72
2005
Capnocytophaga granulosa
brenda
Gasparello-Clemente, E.; Casis, L.; Varona, A.; Gil, J.; Irazusta, J.; Silveira, P.F.
Aminopeptidases in visceral organs during alterations in body fluid volume and osmolality
Peptides
24
1367-1372
2003
Rattus norvegicus
brenda
Cadel, S.; Piesse, C.; Gouzy-Darmon, C.; Cohen, P.; Foulon, T.
Arginyl aminopeptidase
Proteases in Biology and Disease (Hooper, N. M. ; Lendeckel, U. ) Springer
2
113-126
2004
Bos taurus, Homo sapiens, Mus musculus, Rattus norvegicus
-
brenda
Bellemare, A.; Vernoux, N.; Morisset, D.; Bourbonnais, Y.
Human pre-elafin inhibits a Pseudomonas aeruginosa-secreted peptidase and prevents its proliferation in complex media
Antimicrob. Agents Chemother.
52
483-490
2008
Pseudomonas aeruginosa
brenda
Fukasawa, K.M.; Hirose, J.; Hata, T.; Ono, Y.
Aspartic acid 405 contributes to the substrate specificity of aminopeptidase B
Biochemistry
45
11425-11431
2006
Rattus norvegicus
brenda
Hirose, J.; Ohsaki, T.; Nishimoto, N.; Matuoka, S.; Hiromoto, T.; Yoshida, T.; Minoura, T.; Iwamoto, H.; Fukasawa, K.M.
Characterization of the metal-binding site in aminopeptidase B
Biol. Pharm. Bull.
29
2378-2382
2006
Rattus norvegicus
brenda
Pinyol, M.; Bea, S.; Pla, L.; Ribrag, V.; Bosq, J.; Rosenwald, A.; Campo, E.; Jares, P.
Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis
Blood
109
5422-5429
2007
Homo sapiens
brenda
Pham, V.L.; Cadel, M.S.; Gouzy-Darmon, C.; Hanquez, C.; Beinfeld, M.C.; Nicolas, P.; Etchebest, C.; Foulon, T.
Aminopeptidase B, a glucagon-processing enzyme: site directed mutagenesis of the Zn2+-binding motif and molecular modelling
BMC Biochem.
8
21
2007
Rattus norvegicus
brenda
Knotz, S.; Boersma, M.; Saborowski, R.
Microassays for a set of enzymes in individual small marine copepods
Comp. Biochem. Physiol. A
145
406-411
2006
Acartia clausii, Centropages typicus, Corycaeus anglicus, Paracalanus parvus, Temora longicornis
brenda
Bolumar, T.; Sanz, Y.; Aristoy, M.; Toldra, F.
Protease (PrA and PrB) and prolyl and arginyl aminopeptidase activities from Debaryomyces hansenii as a function of growth phase and nutrient sources
Int. J. Food Microbiol.
107
20-26
2006
Debaryomyces hansenii, Debaryomyces hansenii CECT 12487
brenda
Hwang, S.R.; ONeill, A.; Bark, S.; Foulon, T.; Hook, V.
Secretory vesicle aminopeptidase B related to neuropeptide processing: molecular identification and subcellular localization to enkephalin- and NPY-containing chromaffin granules
J. Neurochem.
100
1340-1350
2007
Rattus norvegicus, Bos taurus (A2T1U6), Bos taurus
brenda
Banegas, I.; Prieto, I.; Vives, F.; Alba, F.; de Gasparo, M.; Segarra, A.B.; Hermoso, F.; Duran, R.; Ramirez, M.
Brain aminopeptidases and hypertension
J. Renin Angiotensin Aldosterone Syst.
7
129-134
2006
Rattus norvegicus
brenda
Qu, H.Q.; Marchand, L.; Frechette, R.; Bacot, F.; Lu, Y.; Polychronakos, C.
No association of type 1 diabetes with a functional polymorphism of the LRAP gene
Mol. Immunol.
44
2135-2138
2007
Homo sapiens
brenda
Hui, M.; Hui, K.S.
A novel aminopeptidase with highest preference for lysine
Neurochem. Res.
31
95-102
2006
Rattus norvegicus
brenda
Hwang, S.R.; Hook, V.
Zinc regulation of aminopeptidase B involved in neuropeptide production
FEBS Lett.
582
2527-2531
2008
Rattus norvegicus
brenda
Bogra, P.; Singh, J.; Singh, H.
Immobilization of goat brain aminopeptidase B in calcium alginate beads
Biocatal. Biotransform.
27
96-101
2009
Capra aegagrus
-
brenda
Bogra, P.; Singh, J.; Singh, H.
Purification and characterization of aminopeptidase B from goat brain
Process Biochem.
44
776-780
2009
Capra aegagrus
-
brenda
Sakamoto, Y.; Suzuki, Y.; Iizuka, I.; Tateoka, C.; Roppongi, S.; Okada, H.; Nonaka, T.; Morikawa, Y.; Nakamura, K.; Ogasawara, W.; Tanaka, N.
Crystallization and preliminary X-ray crystallographic studies of dipeptidyl aminopeptidase BII from Pseudoxanthomonas mexicana WO24
Acta Crystallogr. Sect. F
70
221-224
2014
Pseudoxanthomonas mexicana (V5YM14), Pseudoxanthomonas mexicana WO24 (V5YM14), Pseudoxanthomonas mexicana WO24
brenda
Ogawa, Y.; Ohnishi, A.; Goto, Y.; Sakuma, Y.; Watanabe, J.; Hattori, A.; Tsujimoto, M.
Role of glutamine-169 in the substrate recognition of human aminopeptidase B
Biochim. Biophys. Acta
1840
1872-1881
2014
Homo sapiens
brenda
Cadel, S.; Darmon, C.; Pernier, J.; Herve, G.; Foulon, T.
The M1 family of vertebrate aminopeptidases: Role of evolutionarily conserved tyrosines in the enzymatic mechanism of aminopeptidase B
Biochimie
109
67-77
2015
Rattus norvegicus
brenda
Ye, M.; Wysocki, J.; Gonzalez-Pacheco, F.R.; Salem, M.; Evora, K.; Garcia-Halpin, L.; Poglitsch, M.; Schuster, M.; Batlle, D.
Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2
Hypertension
60
730-740
2012
Homo sapiens, Mus musculus
brenda
Cadel, S.; Darmon, C.; Desert, A.; Mahbouli, M.; Piesse, C.; Ghelis, T.; Lafont, R.; Foulon, T.
The effects of curcumin, mangiferin, resveratrol and other natural plant products on aminopeptidase B activity
Biochem. Biophys. Res. Commun.
512
832-837
2019
Rattus norvegicus
brenda
Ohnishi, A.; Watanabe, J.; Ogawa, Y.; Goto, Y.; Hattori, A.; Tsujimoto, M.
Involvement of phenylalanine 297 in the construction of the substrate pocket of human aminopeptidase B
Biochemistry
54
6062-6070
2015
Homo sapiens (Q9H4A4), Homo sapiens
brenda
Zhang, F.; Wu, D.; Wang, G.; Hou, S.; Ou-Yang, P.; Huang, J.; Xu, X.
Synthesis and biological evaluation of novel 1,2,3-benzotriazin-4-one derivatives as leukotriene A4 hydrolase aminopeptidase inhibitors
Chin. Chem. Lett.
28
1044-1048
2017
Homo sapiens (P09960)
-
brenda
Lu, W.; Yao, X.; Ouyang, P.; Dong, N.; Wu, D.; Jiang, X.; Wu, Z.; Zhang, C.; Xu, Z.; Tang, Y.; Zou, S.; Liu, M.; Li, J.; Zeng, M.; Lin, P.; Cheng, F.; Huang, J.
Drug repurposing of histone deacetylase inhibitors that alleviate neutrophilic inflammation in acute lung injury and idiopathic pulmonary fibrosis via inhibiting leukotriene A4 hydrolase and blocking LTB4 biosynthesis
J. Med. Chem.
60
1817-1828
2017
Homo sapiens (P09960)
brenda